MRUS vs. UTHR, RDY, SRPT, CTLT, ELAN, INSM, ROIV, LEGN, ASND, and CERE
Should you be buying Merus stock or one of its competitors? The main competitors of Merus include United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Elanco Animal Health (ELAN), Insmed (INSM), Roivant Sciences (ROIV), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
United Therapeutics (NASDAQ:UTHR) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership.
United Therapeutics received 238 more outperform votes than Merus when rated by MarketBeat users. However, 65.88% of users gave Merus an outperform vote while only 61.84% of users gave United Therapeutics an outperform vote.
United Therapeutics currently has a consensus price target of $309.44, indicating a potential upside of 12.53%. Merus has a consensus price target of $72.70, indicating a potential upside of 37.43%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Merus is more favorable than United Therapeutics.
United Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
United Therapeutics has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
United Therapeutics has a net margin of 42.05% compared to United Therapeutics' net margin of -390.36%. Merus' return on equity of 18.72% beat United Therapeutics' return on equity.
In the previous week, Merus had 4 more articles in the media than United Therapeutics. MarketBeat recorded 21 mentions for Merus and 17 mentions for United Therapeutics. Merus' average media sentiment score of 0.76 beat United Therapeutics' score of 0.31 indicating that United Therapeutics is being referred to more favorably in the media.
94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 12.5% of United Therapeutics shares are owned by insiders. Comparatively, 4.6% of Merus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
United Therapeutics beats Merus on 10 of the 18 factors compared between the two stocks.
Get Merus News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
